BeiGene Ltd.

BeiGene Ltd. logo
🇺🇸United States
Ownership
Public
Established
2010-01-01
Employees
10K
Market Cap
$22.1B
Website
http://www.beigene.com

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2020-12-02
Last Posted Date
2024-10-23
Lead Sponsor
BeiGene
Target Recruit Count
330
Registration Number
NCT04649385
Locations
🇺🇸

Icahn School of Medicine At Mount Sinai, New York, New York, United States

🇦🇺

Ashford Cancer Centre Research Northeast, Windsor Gardens, South Australia, Australia

🇦🇺

Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia

and more 17 locations

Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-11-25
Last Posted Date
2024-11-28
Lead Sponsor
BeiGene
Target Recruit Count
177
Registration Number
NCT04643470
Locations
🇨🇳

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China

🇨🇳

Jiangsu Province Hospital, Nanjing, Jiangsu, China

🇨🇳

Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

and more 41 locations

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2020-09-16
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
181
Registration Number
NCT04551898
Locations
🇺🇸

Btc Network Midland Florida Clinical Research Center, DeLand, Florida, United States

🇺🇸

Elixia Clinical Research Collaborative, Hollywood, Florida, United States

🇧🇷

Consultoria Medica E Pesquisa Clinica, Sorcaba, Brazil

and more 15 locations

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

First Posted Date
2020-09-16
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
26
Registration Number
NCT04551963
Locations
🇦🇺

Concord Repatriation General Hospital, Concord, New South Wales, Australia

🇦🇺

John Flynn Private Hospital, Tugun, Queensland, Australia

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 4 locations

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-08-31
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
18
Registration Number
NCT04532294
Locations
🇦🇺

Q PHARM, Herston, Queensland, Australia

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

First Posted Date
2020-07-24
Last Posted Date
2024-12-13
Lead Sponsor
BeiGene
Target Recruit Count
123
Registration Number
NCT04486391
Locations
🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

🇨🇳

Jilin Cancer Hospital, Changchun, Jilin, China

and more 4 locations

Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-07-15
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
26
Registration Number
NCT04472650
Locations
🇦🇺

Linear Clinical Research, Nedlands, Western Australia, Australia

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-07-14
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
13
Registration Number
NCT04470908
Locations
🇺🇸

Covance Clinical Research Unit, Daytona Beach, Florida, United States

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Posted Date
2020-06-17
Last Posted Date
2024-12-18
Lead Sponsor
BeiGene
Target Recruit Count
66
Registration Number
NCT04436107
Locations
🇨🇳

Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

🇨🇳

Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China

🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

and more 7 locations

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

First Posted Date
2020-05-26
Last Posted Date
2024-10-26
Lead Sponsor
BeiGene
Target Recruit Count
64
Registration Number
NCT04401800
Locations
🇨🇳

Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China

🇨🇳

Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

🇨🇳

The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, China

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath